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Abstract 
Introduction: 
 Ovarian cancer is the second most common gynecological malignancy.  
Most cases are diagnosed late, because effective screening methods are not 
available and the malignancy is often asymptomatic for a long time. 
 Surgical resection of the tumor remains the cornerstone of treatment. But 
in 70% of patients with advanced disease optional debulking cannot be 
obtained.  Interval debulking surgery after giving neo adjuvant chemotherapy 
helps in optimal debulking and improved the overall survival.  
Aim: 
 The aim of the study is to know the tumor clearance effect of neo 
adjuvant chemotherapy in advanced chemotherapy in terms of optimal 
debulking ascitic fluid volume reduction, blood transfusion requirements and to 
compare it with those who have not received neo adjuvant chemotherapy. 
Methods:  
 This is a prospective study, conducted in patients with advanced ovarian 
carcinoma. Patients who underwent IDS for stage IIIC or IV advanced ovarian 
carcinoma were selected for the study and the results were compared with those 
who underwent primary debulking surgery. 
Conclusion: 
 Neo adjuvant chemotherapy is significantly more effective in achieving 
optimal cytoreduction and reducing ascitic fluid volume in advanced ovarian 
cancer.  
 Blood transfusion is significantly less in neo adjuvant chemotherapy 
group.   
 Adhesions are found to be significantly less in NACT group. 
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